Skip to search formSkip to main contentSkip to account menu

laquinimod

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Laquinimod is an orally dosed immuno-modulator currently under development for Huntington’s disease (HD). Preclinical findings… 
2017
2017
MS diagnosis and prognosis is based on a combination of clinical criteria, MRI, and CSF findings. However, we still lack the… 
2016
2016
Objective: To test whether Toll-like receptor (TLR) signaling plays a key role for reduced nuclear factor B (NF-κB) activation… 
2015
Review
2014
Review
2014
The most significant data presented at the 28th Congress of the European Committee for Treatment and Research in Multiple… 
Review
2011
Review
2011
Introduction: MS is a chronic immunological disease of the CNS. Due to a lack of curative treatment approaches, current… 
2006
2006
5-Chloro-N-ethyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide (laquinimod, 2) is an oral drug in clinical… 
2003
2003
Multiple sclerosis (MS) is an inflammatory, demyelinating disorder of the central nervous system (CNS) characterized by focal…